安罗替尼在肿瘤患者真实世界治疗中的用药特征和监护要点  

Drug characteristics and monitoring points of anlotinib in real world treatment of cancer patients

作　　者：张夏兰 袁静 吴斌[1] ZHANG Xialan;YUAN Jing;WU Bin(Department of Pharmacy,Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Jiangsu Suzhou 215009,China)

机构地区：[1]南京中医药大学附属苏州市中医医院药学部,江苏苏州215009

出　　处：《现代肿瘤医学》2024年第9期1663-1668,共6页Journal of Modern Oncology

基　　金：江苏省药学会天晴医院药学科研项目(编号:Q202026);江苏省苏州市民生科技-医疗卫生应用基础研究项目(编号:SYSD2020193)。

摘　　要：目的:分析真实世界中安罗替尼用药特征和监护要点。方法:采用回顾性调查,通过His系统收集本院2020年01月01日至2022年12月31日期间使用安罗替尼的患者治疗信息,统计患者基本情况、用药信息、临床疗效和不良反应。结果:共纳入98例服用安罗替尼的患者,其中男性60例,女性38例,平均年龄为(63.08±9.22)岁,多为肺癌、胆管癌、输卵管癌等Ⅳ期肿瘤患者,患者的中医证型多为气阴两虚或脾虚湿阻;KPS评分主要集中在80分和70分。患者用药前,白细胞偏低,转氨酶偏高、血钠偏低和甲状腺功能异常较常见。患者服用安罗替尼多为10 mg qd,单独用药、联合免疫药物或中成药较多。约52.04%患者影像学评价为部分缓解和稳定,29.59%患者进展;常见不良反应有乏力疲劳、尿蛋白阳性、血压升高和血小板减少。结论:医师应重视安罗替尼的安全、合理使用,临床药师应做好用药交代,关注安罗替尼与其他药物的相互作用,加强监测相关不良事件,尤其血压升高、出血、蛋白尿阳性、甲状腺功能减退及血小板计数降低等不良反应,降低用药风险。Objective:To analyze the characteristics and main points of monitoring of anlotinib therapy in the real world.Methods:A retrospective investigation was conducted to summarize the treatment information of patients who used anlotinib in our hospital from 1st January 2020 to 31st December 2022 through His system.We collected the basic information of patients,medication information,clinical efficacy and adverse reactions.Results:A total of 98 patients taking anlotinib were included.There were 60 males and 38 females with an average age of(63.08±9.22)years old.The anlotinib was mainly used for lung cancer,bile duct cancer,fallopian tube cancer of stageⅣtumor patients.Most of the TCM syndrome types were Qi-yin deficiency or spleen deficiency dampness.The KPS scores of patients were mainly 80 and 70 points.Before medication,low white blood cells,high transaminase,low blood sodium and abnormal thyroid function were common.Most of the patients took 10mg qd of anlotinib.More patients took allotinib alone,combined with immune drugs or proprietary Chinese medicines.About 52.04%of the patients had partial response and stability,and 29.59%had progress.Common adverse reactions were fatigue,positive urinary protein,elevated blood pressure,and thrombocytopenia.Conclusion:Doctors should pay attention to the safety and rational use of anlotinib.Clinical pharmacists should do a good job of medication replacement and pay attention to the interaction between anrotinib and other drugs.Clinical pharmacists should strengthen monitoring of related adverse events,especially such as elevated blood pressure,bleeding,positive proteinuria,hypothyroidism and decreased platelet count.We aim to reduce the risk of medication.

关 键 词：安罗替尼 真实世界 肿瘤患者 合理用药 不良反应 药学监护 

分 类 号：R730.5[医药卫生—肿瘤]